uniQure (QURE) EBITDA Margin Growth (1y) (2017 - 2026)
Powered by 
Analysis
uniQure (QURE) EBITDA Margin Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.26 Bn | 9.41 Bn | 112.79 Mn | 798.00 |
| 2 | CRISPR Therapeutics AG | 5.18 Bn | 5.18 Bn | - | 2.46 Mn |
| 3 | Iovance Biotherapeutics | 3.80 Bn | 3.50 Bn | 55.72 Mn | 13,751.00 |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 2,348.00 |
| 5 | uniQure | 3.04 Bn | 3.04 Bn | 5.49 Mn | -6,012.00 |
| 6 | Beam Therapeutics | 2.64 Bn | 2.64 Bn | - | -2.44 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 375,193.00 |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | -1,560.00 |
| 9 | Vericel | 1.98 Bn | 1.82 Bn | 56.40 Mn | 377.00 |
| 10 | Taysha Gene Therapies | 1.97 Bn | 1.97 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -6,012.00 |
| Mar 31, 2026 | 122,641.00 |
| Dec 31, 2025 | -4,030.00 |
| Sep 30, 2025 | 38,003.00 |
| Jun 30, 2025 | -43,806.00 |
| Mar 31, 2025 | -187,085.00 |
| Dec 31, 2024 | 4,536.00 |
| Sep 30, 2024 | 406,028.00 |
| Jun 30, 2024 | 229,123.00 |
| Mar 31, 2024 | 75,380.00 |
| Dec 31, 2023 | -94,892.00 |
| Sep 30, 2023 | -171,174.00 |
| Jun 30, 2023 | 859,309.00 |
| Mar 31, 2023 | 162,496.00 |
| Dec 31, 2022 | 2,221.00 |
| Sep 30, 2022 | -184,508.00 |
| Jun 30, 2022 | -1.14 Mn |
| Mar 31, 2022 | 677,465.00 |
| Dec 31, 2021 | 2,783.00 |
| Sep 30, 2021 | 22,442.00 |